A small molecule kinase inhibitor, LRRK2-IN-1, was first reported to regulate DCLK1-mediated stemness and EMT by suppressing DCLK1 kinase activity in colorectal and pancreatic cancer [80]. Here, DCLK1 is linked to familial pancreatic carcinoma.